What the Keytruda TV commercial - Teresa: Family is about.
Keytruda is a drug that is designed to help treat certain types of cancer, and the TV spot titled 'Teresa: Family' is an emotional portrayal of how this drug can help cancer patients continue to live fulfilling lives.
The ad introduces viewers to Teresa, a cancer survivor who speaks about the importance of family during her cancer journey. She speaks about how her family has been her rock and how their love and support helped her to power through her cancer treatments.
Throughout the video, viewers see glimpses of Teresa's life - the sound of her grandchildren laughing, her sitting across from her husband at dinnertime, and other tender moments.
Teresa also shares that despite having stage four cancer, she's still alive and active thanks to KEYTRUDA, her cancer drug. As she speaks about her treatment, viewers see her taking her medication and spending precious moments with her loved ones.
The TV spot conveys that the support of loved ones is crucial in a cancer patient's journey, and that KEYTRUDA can enable patients to continue experiencing such moments and maintaining their quality of life.
Overall, the Keytruda TV spot 'Teresa: Family' is a poignant reminder of the power of family, love, and modern medicine in helping people overcome cancer and maintain a fulfilling life.
Keytruda TV commercial - Teresa: Family produced for
Keytruda
was first shown on television on May 11, 2021.
Frequently Asked Questions about keytruda tv spot, 'teresa: family'
Since then, Theresa has been undetectable for over a year, and she continues treatment with Keytruda, with little to no side effects. Her family remains hopeful and grateful that everything is going well for Theresa and they pray for her continued strength.
Sharon says she learned her type of lung cancer could be treated with an alternative to chemo. She tells how she was given only months to live but a year later after treatment she is still there with her family. The commercial is filmed in black and white which adds to the seriousness of the presentation.
KEYTRUDA is a prescription medicine used to treat a kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread, and tests positive for “PD-L1.”
The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $11,115.04. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $22,230.08. * Most people will not pay the list price, although it may have an impact on your out-of-pocket costs.
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with ...
Keytruda is not only Merck & Co.'s top product but also one of the best-selling drugs worldwide, generating nearly 21 billion U.S. dollars in revenue during 2022.
Pembrolizumab (pronounced pem-bro-lih-zoo-mab) is a type of immunotherapy. It is also known by its brand name, Keytruda. You might have it as a treatment by itself or in combination with another treatment for a number of different cancer types.
KEYTRUDA blocks the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.
Keytruda works by binding to PD-1 and therefore blocking the cancer cells from using their own protein to slot into the same spot and switch off the immune cells. So with Keytruda, the T-cells do their job and effectively attack the cancer. Keytruda is also known as an anti PD-1 immunotherapy.
The drug, which is also known as Keytruda, would have cost around £84,000 per patient at its full list price. NHS England and MSD have agreed a confidential arrangement for reimbursement which will enable NICE to recommend it be routinely available on the NHS.
Some patients can stay on KEYTRUDA for up to a year or two. Your doctor will decide how long you will be on treatment.
While Merck & Co has been responsible for Keytruda's commercial success, the drug was originally developed by a team of Dutch scientists now at Aduro Biotech, which develops immunotherapies for cancer and is also using its technology to target autoimmune and infectious diseases.